[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"copd-acute-exacerbation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:copd-acute-exacerbation":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,48,80],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100588342",false,"NCT06940154","Rademikibart Add-on Treatment of an Acute COPD Exacerbation (Seabreeze STAT COPD)","A Phase 2, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Rademikibart as an Add-on Treatment for Acute Exacerbation in Participants With Chronic Obstructive Pulmonary Disease and Type 2 Inflammation","Inclusion Criteria:\n\n* Physician-diagnosed COPD with duration of ≥12 months.\n* Must have experienced at least 1 COPD exacerbation requiring the use of systemic corticosteroids.\n* Participants in a stable condition must have a documented historical peripheral blood eosinophil count of ≥250 cells\u002FμL and\u002For FeNO ≥ 25 ppb.\n* Current or former smoker with a history of smoking of ≥10 pack-years.\n* Current acute COPD exacerbation requiring an urgent healthcare visit for treatment.\n* Peripheral blood eosinophil count of ≥300 cells\u002FμL as part of the assessment of the index acute COPD exacerbation.\n* Requires systemic corticosteroids as standard of care treatment in the urgent healthcare setting for the current acute COPD exacerbation.\n\nExclusion Criteria:\n\n* Regular use of immunosuppressive medication 12 weeks or 5 half-lives prior to randomization, whichever is longer.\n* Current diagnosis or a history of asthma, according to the Global Initiative for Asthma; or participants with a current diagnosis or history of Asthma COPD Overlap Syndrome.\n* Other respiratory disorders that might compromise the safety of the participant or affect the interpretation of the results.\n* Unstable ischemic heart disease, cardiomyopathy, heart failure (New York Heart Association Class III or IV), uncontrolled hypertension. Cardiac arrhythmias including paroxysmal atrial fibrillation.\n* Transient ischemic attack or stroke \\\u003C6 months from Screening Visit; hospitalization for any cardiovascular or cerebrovascular event \\\u003C6 months from Screening Visit.\n* Known or suspected history of immunosuppression.\n* History of known immunodeficiency disorder or hepatitis B or C.\n* History of alcohol abuse and\u002For drug abuse.\n* Recent history of cancer except basal cell carcinoma or in situ carcinoma of the cervix treated with apparent success.\n* Chronic treatment with long-term oxygen therapy (LTOT) or nocturnal oxygen therapy required for \\>15 hours a day.\n* Participants on long-term macrolide.\n* Current acute COPD exacerbation for which SoC was started \\>48 hours prior to Screening.\n* A recent chest X-ray or computed tomography (CT) scan at Screening reveals evidence of clinically significant abnormalities not believed to be due to the presence of COPD, or a clinically significant pulmonary infection identified by chest X-ray (CT scan).\n* Female participant who is pregnant, lactating or breast-feeding, or has a positive urinary β-hCG test prior to randomization.\n* Receipt of any marketed nonbiologic drug that modulates type 2 cytokines 30 days or 5 half-lives prior to randomization, whichever is longer.\n* Receipt of any marketed or any investigational biologic for COPD or other diseases within 16 weeks or 5 half-lives prior to randomization, whichever is longer.\n* Live, attenuated vaccinations within 4 weeks prior to randomization or planned live, attenuated vaccinations during the trial.\n* Treatment with systemic corticosteroids (ie, oral or by injection) and\u002For hospitalization for an exacerbation of COPD completed less than 4 weeks prior to randomization.\n\nThe above inclusion and exclusion criteria are not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.","ALL","40 Years","80 Years",{"count":19,"type":20},160,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","This is a Phase 2, multicenter study in adult participants with an acute COPD exacerbation and type 2 inflammation",[26],"COPD Acute Exacerbation",[28,29,30,31,32,33,34],"COPD","chronic obstructive pulmonary disease","rademikibart","Connect Biopharma","CBP-201","COPD exacerbation","type 2 inflammation","RECRUITING","2026-06-10",{"date":38,"type":39},"2026-06-12","ACTUAL",{"date":41,"type":39},"2025-08-12",{"date":43,"type":20},"2026-07",{"name":45,"class":46},"Connect Biopharm LLC","INDUSTRY",53,{"id":49,"slug":50,"hasResults":10,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":56,"targetDuration":4,"studyType":21,"phases":58,"briefSummary":60,"conditions":61,"keywords":67,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":4},"100620748","the-revive-pivotal-study-100620748","NCT07361653","The REVIVE Pivotal Study","A Prospective, Global, Multicenter, Randomized, Double Blind, Sham Controlled Study to EValuate the Safety and effectIVEness of the Ryme Medical Targeted Lung Denervation (TLD) Catheter in Patients With Moderate and Severe Symptomatic Chronic Obstructive Pulmonary Disease (COPD) - The REVIVE Pivotal Study","REVIVE","Inclusion Criteria:\n\n* Symptomatic chronic obstructive pulmonary disease\n* History of COPD exacerbation(s)\n* Stable medical therapy\n* Candidate for bronchoscopy\n\nExclusion Criteria:\n\n* Prior lung intervention with device in place\n* Using tobacco products, e-cigarettes, vape or other inhaled non-pharmacological substance\n* Clinically significant serious or unstable medical conditions (e.g., heart disease requiring treatment, uncontrolled diabetes)\n* Pregnant, nursing, or intent to become pregnant during study duration",{"count":57,"type":20},300,[59],"NA","The goal of this study is to test whether a new treatment called the Ryme Medical Targeted Lung Denervation (TLD) Catheter is safe and effective for people with moderate to severe chronic obstructive pulmonary disease (COPD).\n\nThe main questions it aims to answer are:\n\n1. Does the TLD Catheter improve symptoms in people with COPD?\n2. Is the TLD Catheter safe ?\n\nResearchers will compare the group receiving the TLD treatment to the group receiving a sham procedure to see if the treatment improves quality of life.\n\nParticipants will:\n\n1. Be randomly assigned to receive either the TLD treatment or a sham procedure.\n2. Undergo the assigned procedure in a hospital setting.\n3. Attend follow-up visits for health checks and breathing tests.",[62,63,64,26,28,65,66],"COPD (Chronic Obstructive Pulmonary Disease)","COPD Exacerbations","COPD Patients","Lung Disease Airways","Lung Disease, Chronic Obstructive",[28,68,69],"Targeted Lung Denervation","Chronic Obstructive Pulmonary Disease","NOT_YET_RECRUITING","2026-04-29",{"date":73,"type":39},"2026-05-05",{"date":75,"type":20},"2026-06",{"date":77,"type":20},"2029-12",{"name":79,"class":46},"Ryme Medical, Inc.",{"id":81,"slug":82,"hasResults":10,"nctId":83,"briefTitle":84,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":10,"sex":15,"minAge":86,"maxAge":87,"enrollmentInfo":88,"targetDuration":4,"studyType":21,"phases":90,"briefSummary":91,"conditions":92,"keywords":95,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":107},"100594495","efficacy-of-inpatient-pulmonary-rehabilitation-program-in-elderly-patients-with-acute-exacerbation-of-copd-100594495","NCT07020182","Efficacy Of Inpatient Pulmonary Rehabilitation Program In Elderly Patients With Acute Exacerbation Of COPD","Inclusion Criteria:\n\n* Patients with acute exacerbation of COPD in both gender\n* Patient older than 65 years\n* Patient with clear consciousness\n* Patients had been diagnosed with shortness of breath or dyspnea that was not caused by heart disease, pneumothorax, or pulmonary edema\n\nExclusion Criteria:\n\n* Patient with systolic blood pressure lower than 90 mmHg\n* Patient with an unstable psychological status, hemoptysis, pneumothorax, pulmonary edema","65 Years","78 Years",{"count":89,"type":20},60,[59],"The study aimed to identify the effect of early pulmonary rehabilitation in elderly patients with Acute exacerbation (AE) of COPD (AECOPD) in exercise tolerance, dyspnea, sleep quality, fatigue, and time to discharge from hospital.",[93,94,28,26],"COPD Received PR","Elderly (People Aged 65 or More)",[96],"Elderly patients with acute exacerbation of COPD","2025-06-05",{"date":99,"type":39},"2025-06-13",{"date":101,"type":20},"2025-06-10",{"date":103,"type":20},"2025-09-15",{"name":105,"class":106},"Al-Azhar University","OTHER",1]